Prostate Biopsy Devices Market Size, Share, Growth, and Industry Analysis, By Type (Reusable Devices,Disposable Devices), By Application (Hospitals,Ambulatory Surgical Center (ASCs),Diagnostic Centers), Regional Insights and Forecast to 2035

Prostate Biopsy Devices Market Overview

The global Prostate Biopsy Devices Market is forecast to expand from USD 699.93 million in 2026 to USD 755.73 million in 2027, and is expected to reach USD 1395.25 million by 2035, growing at a CAGR of 7.97% over the forecast period.

The Prostate Biopsy Devices Market is expanding steadily as prostate cancer continues to be the second most diagnosed cancer in men worldwide, with more than 1.4 million new cases reported in 2020 according to global cancer registries. The rising burden of prostate cancer, which accounts for nearly 7.3% of all male cancers, has driven increased demand for advanced biopsy techniques. In 2022, approximately 70% of prostate cancer diagnoses globally were confirmed using biopsy devices, making them a critical component in diagnostic pathways.

The market has seen continuous improvements in device precision, with transrectal and transperineal biopsy techniques being widely adopted. Nearly 85% of hospital-based prostate biopsies rely on ultrasound-guided systems, while MRI-targeted biopsy has gained traction, accounting for around 25% of procedures in developed regions. Manufacturers are increasingly focusing on disposable biopsy needles due to infection control concerns, with disposable devices contributing to nearly 40% of device utilization in 2023.

The United States holds a leading position in the Prostate Biopsy Devices Market due to its advanced healthcare infrastructure and high prevalence of prostate cancer. In 2023, prostate cancer represented 14% of all male cancer cases in the U.S., making biopsy devices essential in clinical settings. Approximately 1 million prostate biopsies are conducted annually in the country, supported by strong guidelines from the American Urological Association that emphasize early diagnosis.

More than 65% of prostate biopsies in the U.S. are conducted using ultrasound-guided techniques, while MRI-fusion biopsy has been adopted by over 30% of tertiary hospitals. Disposable biopsy needles are used in about 45% of all biopsy procedures, reflecting strict infection control protocols. With over 6,000 urologists practicing nationwide, the demand for biopsy devices remains consistent across hospitals, outpatient centers, and specialized diagnostic clinics.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Early cancer detection programs enable 67% localized-stage diagnosis, boosting demand for advanced prostate biopsy devices globally.
• Major Market Restraint: High device costs restrict adoption, affecting 28% of low-income healthcare facilities, limiting access to advanced biopsy technologies worldwide.
• Emerging Trends: MRI-guided biopsies increased adoption by 34% between 2020–2023, improving accuracy and reducing repeat procedures in developed healthcare systems.
• Regional Leadership: North America accounted for 41% of total global share in 2023, maintaining leadership due to advanced healthcare systems and higher screening rates.
• Competitive Landscape: Top five companies captured 52% of global market presence, with Bard and Cook Medical holding the largest shares in 2023.
• Market Segmentation: Disposable biopsy devices held 39% usage share, while reusable devices maintained dominance with 61% utilization, driven by cost-efficiency in high-volume centers.
• Recent Development: Robotic-assisted biopsy procedures grew by 22% between 2021–2023, reflecting increased investment in precision technologies across hospital networks globally.

Prostate Biopsy Devices Market Latest Trends

The Prostate Biopsy Devices Market has witnessed rapid transformation driven by technology adoption and innovation. MRI-targeted biopsy has grown significantly, with studies showing that 92% of clinically significant prostate cancers can be detected using targeted biopsy compared to standard systematic biopsy. This has encouraged leading hospitals to invest in fusion-guided biopsy systems.

Disposable biopsy needles are another key trend, with global usage increasing from 32% in 2018 to 39% in 2023, reflecting greater emphasis on infection control and patient safety. Robotic platforms are reshaping the market landscape, as robotic-assisted prostate biopsies now account for nearly 20% of procedures in top-tier hospitals. Additionally, the transition from transrectal to transperineal approaches has gained momentum, with 56% of European centers adopting transperineal biopsy due to reduced infection rates.

Prostate Biopsy Devices Market Dynamics

DRIVER

"Rising demand for minimally invasive diagnostic procedures."

Minimally invasive biopsy devices have become a central driver in the Prostate Biopsy Devices Market, with nearly 74% of procedures globally relying on less invasive methods in 2023. The adoption of transperineal approaches, which reduce infection risk by 90% compared to transrectal biopsy, has grown significantly.

RESTRAINT

"High procedural and device costs."

The cost of advanced biopsy devices remains a restraint, particularly in developing nations where nearly 35% of healthcare facilities report affordability issues. MRI-guided biopsy equipment requires significant investment in imaging technology, limiting adoption across smaller diagnostic centers.

OPPORTUNITY

"Technological advancements in fusion and robotic biopsy systems."

The opportunity for growth lies in advanced diagnostic technologies, as robotic-assisted biopsy systems are showing adoption growth of 22% annually in top hospitals. Fusion-guided biopsy has proven to improve cancer detection accuracy by 15%, reducing the number of unnecessary repeat biopsies.

CHALLENGE

"Shortage of skilled professionals."

Despite advancements in device technology, the shortage of skilled urologists remains a challenge. The World Health Organization reports that nearly 48% of low-income countries face a shortage of trained specialists, restricting access to advanced biopsy procedures.

Prostate Biopsy Devices Market Segmentation

The Prostate Biopsy Devices Market is segmented by type and application. Reusable devices hold 61% share due to cost efficiency, while disposables account for 39% with infection control advantages. Hospitals perform 68% of biopsies, ASCs 19%, and diagnostic centers 13%, showing diverse adoption patterns across healthcare facilities globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Reusable Devices: Reusable prostate biopsy devices account for nearly 61% of global usage, as hospitals continue to rely on durable systems for cost efficiency. These devices are particularly prevalent in public healthcare systems, where budget constraints necessitate reuse with sterilization protocols. Studies indicate that reusable biopsy guns can withstand more than 500 cycles of sterilization, making them practical for high-volume diagnostic centers.

The Reusable Devices segment in the Prostate Biopsy Devices Market reached USD 389.45 million in 2025, holding 60.1% share, projected to grow to USD 747.12 million by 2034 at a 7.45% CAGR, supported by continued adoption in hospitals and diagnostic centers worldwide.

Top 5 Major Dominant Countries in the Reusable Devices Segment

• United States: With a market size of USD 128.65 million in 2025 and a projected USD 249.88 million by 2034, the U.S. dominates reusable prostate biopsy devices at 7.62% CAGR.
• Germany: Germany’s reusable device market stood at USD 41.32 million in 2025 and is forecasted to reach USD 78.45 million by 2034, maintaining growth at 7.25% CAGR.
• China: In 2025, China achieved USD 56.11 million market size, expected to expand toward USD 106.78 million by 2034, reflecting strong hospital adoption at 7.48% CAGR.
• Japan: Japan’s market for reusable biopsy devices was USD 37.25 million in 2025, projected to reach USD 70.67 million by 2034, continuing expansion at a 7.18% CAGR.
• United Kingdom: The UK accounted for USD 32.54 million in 2025, anticipated to grow steadily toward USD 61.21 million by 2034, with usage expanding at 7.40% CAGR.

Disposable Devices: Disposable prostate biopsy devices have increased in adoption, representing 39% of usage share globally in 2023. Their growth is attributed to strict infection control guidelines and regulatory compliance, particularly in North America and Europe. Clinical data indicates that disposable needles reduce cross-contamination risk by 95% compared to reusable counterparts.

The Disposable Devices segment in the Prostate Biopsy Devices Market achieved USD 258.81 million in 2025, representing 39.9% share, anticipated to reach USD 545.14 million by 2034 at a 8.69% CAGR, driven by infection control priorities and expanding use of single-use needles globally.

Top 5 Major Dominant Countries in the Disposable Devices Segment

• United States: The U.S. disposable devices market recorded USD 94.11 million in 2025, expected to grow robustly to USD 209.78 million by 2034, expanding strongly at an 8.92% CAGR.
• Germany: Germany reported USD 29.18 million in 2025, projected to rise consistently toward USD 62.41 million by 2034, highlighting its expanding adoption of disposables at an 8.70% CAGR.
• China: China’s disposable biopsy devices market reached USD 36.02 million in 2025, anticipated to advance steadily toward USD 77.85 million by 2034, sustaining growth momentum at an 8.52% CAGR.
• Japan: Japan registered USD 26.44 million in 2025, projected to nearly double to USD 56.78 million by 2034, marking sustained growth in disposables at an 8.79% CAGR.
• United Kingdom: The UK market size stood at USD 23.06 million in 2025, expected to increase to USD 49.55 million by 2034, reflecting reliable growth at 8.63% CAGR.

BY APPLICATION

Hospitals: Hospitals remain the largest application segment, performing nearly 68% of global prostate biopsies. Large-scale tertiary care centers invest heavily in MRI-targeted and robotic-assisted biopsy platforms, with over 60% of advanced devices installed in hospital settings.

Hospitals accounted for the largest application, reaching USD 389.98 million in 2025 with 60.1% share, expected to expand to USD 772.85 million by 2034 at a 7.91% CAGR, driven by their role as primary providers of advanced prostate cancer diagnostics worldwide.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: With USD 134.35 million in 2025, the U.S. hospitals market is forecast to reach USD 266.42 million by 2034, maintaining leading dominance at a 7.96% CAGR.
• Germany: Germany recorded USD 40.12 million in 2025, projected to grow steadily toward USD 79.34 million by 2034, reflecting strong healthcare investment with a 7.98% CAGR.
• China: China’s hospital biopsy devices reached USD 55.08 million in 2025, anticipated to achieve USD 107.78 million by 2034, sustaining rapid expansion with a 7.90% CAGR.
• Japan: Japan stood at USD 36.77 million in 2025, projected to grow consistently to USD 71.45 million by 2034, highlighting continued demand at a 7.84% CAGR.
• United Kingdom: The UK hospitals segment was USD 32.10 million in 2025, forecasted to increase to USD 62.01 million by 2034, reflecting steady growth at a 7.82% CAGR.

Ambulatory Surgical Centers (ASCs): ASCs contribute approximately 19% of global biopsy procedures, with growth fueled by the increasing shift toward outpatient diagnostic services. Cost-effectiveness and patient convenience make ASCs important for expanding access to prostate biopsy procedures.

The ASCs application accounted for USD 155.58 million in 2025 with 24.0% share, expected to grow to USD 316.67 million by 2034 at a 8.02% CAGR, fueled by outpatient procedures and increasing adoption of cost-effective biopsy services.

Top 5 Major Dominant Countries in the ASCs Application

• United States: U.S. ASCs held USD 54.44 million in 2025, projected to expand strongly toward USD 111.48 million by 2034, maintaining leadership across outpatient procedures at an 8.09% CAGR.
• Germany: Germany recorded USD 16.73 million in 2025, expected to double to USD 34.18 million by 2034, underscoring growth in outpatient biopsy services at an 8.01% CAGR.
• China: China’s ASCs segment stood at USD 22.45 million in 2025, forecast to reach USD 45.83 million by 2034, reflecting robust adoption trends at an 8.03% CAGR.
• Japan: Japan accounted for USD 15.16 million in 2025, anticipated to hit USD 30.73 million by 2034, marking continued preference for outpatient solutions at an 8.00% CAGR.
• United Kingdom: The UK registered USD 13.22 million in 2025, projected to grow toward USD 26.91 million by 2034, highlighting reliable adoption growth at an 8.05% CAGR.

Diagnostic Centers: Diagnostic centers perform nearly 13% of prostate biopsies, often relying on reusable ultrasound-guided devices. In urban areas of Asia-Pacific, diagnostic centers account for 22% of biopsy procedures, providing affordable alternatives to hospital-based care.

The Diagnostic Centers application accounted for USD 102.70 million in 2025, representing 15.9% share, projected to grow to USD 202.74 million by 2034 at a 7.92% CAGR, supported by affordability and accessibility for widespread prostate cancer screening services.

Top 5 Major Dominant Countries in the Diagnostic Centers Application

• United States: U.S. diagnostic centers reached USD 36.11 million in 2025, projected to achieve USD 71.68 million by 2034, sustaining strong diagnostic testing demand at a 7.94% CAGR.
• Germany: Germany’s diagnostic centers held USD 11.65 million in 2025, forecasted to expand to USD 23.12 million by 2034, reflecting stable service adoption at a 7.92% CAGR.
• China: China recorded USD 15.89 million in 2025, projected to grow toward USD 31.46 million by 2034, highlighting growing diagnostic infrastructure at a 7.91% CAGR.
• Japan: Japan’s diagnostic centers stood at USD 10.88 million in 2025, anticipated to reach USD 21.43 million by 2034, ensuring reliable growth at a 7.87% CAGR.
• United Kingdom: The UK registered USD 9.61 million in 2025, expected to expand to USD 18.85 million by 2034, maintaining consistent diagnostic adoption at a 7.89% CAGR.

Prostate Biopsy Devices Market Regional Outlook

The global Prostate Biopsy Devices Market shows strong growth potential. North America leads with 41% share, Europe holds 28%, Asia-Pacific accounts for 22%, and Middle East & Africa contribute 9%. Advancements in MRI-guided and robotic-assisted biopsies, along with rising cancer incidence, support expanding device adoption across all regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America leads the Prostate Biopsy Devices Market, accounting for 41% of global market share in 2023. The high prevalence of prostate cancer, with 288,000 new cases reported in the U.S., supports large-scale adoption of advanced biopsy devices. MRI-targeted and robotic-assisted biopsies have expanded rapidly across hospitals, with disposable needles representing nearly 45% of U.S. procedures.

The North America Prostate Biopsy Devices Market valued at USD 265.51 million in 2025 with 40.9% share, projected to reach USD 512.64 million by 2034 at a 7.71% CAGR, supported by strong adoption of advanced diagnostic technologies and widespread screening programs.

North America - Major Dominant Countries in the Prostate Biopsy Devices Market

• United States: With USD 223.76 million in 2025, the U.S. is projected to achieve USD 431.44 million by 2034, retaining global leadership in biopsy devices at a 7.80% CAGR.
• Canada: Canada recorded USD 19.18 million in 2025, forecast to expand steadily toward USD 36.32 million by 2034, maintaining consistent healthcare demand for devices at a 7.65% CAGR.
• Mexico: Mexico reached USD 14.07 million in 2025, projected to hit USD 26.82 million by 2034, showcasing rising prostate cancer diagnostics adoption at a 7.61% CAGR.
• Cuba: Cuba’s market stood at USD 4.71 million in 2025, expected to grow toward USD 8.96 million by 2034, highlighting improving diagnostic coverage at a 7.55% CAGR.
• Dominican Republic: With USD 3.79 million in 2025, Dominican Republic is forecasted to reach USD 7.10 million by 2034, sustaining modest regional demand growth at a 7.52% CAGR.

EUROPE

Europe follows closely, contributing 28% of global share, supported by strong adoption of transperineal approaches. In 2023, 56% of European hospitals reported exclusive use of transperineal biopsy, reducing infection risks. Germany, France, and the UK remain primary adopters of MRI-fusion devices, with disposable devices accounting for nearly 38% of use across Europe.

The Europe Prostate Biopsy Devices Market valued at USD 181.50 million in 2025 with 28.0% share, projected to reach USD 364.08 million by 2034 at a 8.00% CAGR, supported by growing adoption of MRI-guided and transperineal biopsy techniques across major healthcare systems.

Europe - Major Dominant Countries in the Prostate Biopsy Devices Market

• Germany: Germany accounted for USD 57.05 million in 2025, projected to reach USD 114.71 million by 2034, reflecting its leadership in advanced biopsy solutions at an 8.04% CAGR.
• United Kingdom: UK market size was USD 46.51 million in 2025, expected to grow toward USD 93.31 million by 2034, highlighting robust healthcare adoption at an 8.02% CAGR.
• France: France recorded USD 34.82 million in 2025, projected to expand steadily to USD 69.90 million by 2034, supported by hospital diagnostic demand at a 7.98% CAGR.
• Italy: Italy’s market stood at USD 25.41 million in 2025, forecasted to reach USD 51.25 million by 2034, sustaining steady growth in biopsy procedures at a 7.95% CAGR.
• Spain: Spain recorded USD 17.71 million in 2025, projected to achieve USD 35.23 million by 2034, reflecting expanding healthcare investment and biopsy adoption at a 7.94% CAGR.

ASIA-PACIFIC

Asia-Pacific demonstrates the fastest expansion, contributing 22% of global market share in 2023. Rising healthcare infrastructure investment in China, Japan, and India has boosted biopsy adoption. Approximately 160,000 new prostate cancer cases were reported in China in 2022, with hospitals accounting for more than 70% of biopsy procedures.

The Asia-Pacific Prostate Biopsy Devices Market stood at USD 142.20 million in 2025, capturing 21.9% share, expected to reach USD 296.51 million by 2034 at a 8.49% CAGR, fueled by rising prostate cancer prevalence and expanding healthcare infrastructure.

Asia-Pacific - Major Dominant Countries in the Prostate Biopsy Devices Market

• China: China recorded USD 68.47 million in 2025, projected to rise to USD 143.34 million by 2034, reflecting dominant adoption of biopsy devices at an 8.56% CAGR.
• Japan: Japan’s market size stood at USD 46.74 million in 2025, expected to grow toward USD 97.49 million by 2034, demonstrating reliable adoption at an 8.47% CAGR.
• India: India accounted for USD 22.61 million in 2025, forecasted to expand steadily to USD 47.36 million by 2034, supported by rising diagnostics demand at an 8.44% CAGR.
• South Korea: South Korea reached USD 18.25 million in 2025, projected to achieve USD 38.25 million by 2034, reflecting expanding biopsy device penetration at an 8.39% CAGR.
• Australia: Australia’s market stood at USD 14.13 million in 2025, expected to hit USD 29.57 million by 2034, maintaining steady adoption growth at an 8.37% CAGR.

MIDDLE EAST & AFRICA

The Middle East & Africa contribute 9% of the market share, with adoption driven by urban hospitals in Gulf nations. South Africa and Saudi Arabia are leading markets, with increasing use of disposable biopsy devices, accounting for 32% of procedures in the region.

The Middle East and Africa Prostate Biopsy Devices Market valued at USD 59.05 million in 2025 with 9.1% share, projected to reach USD 118.03 million by 2034 at a 7.91% CAGR, supported by diagnostic expansion in Gulf countries and South Africa.

Middle East and Africa - Major Dominant Countries in the Prostate Biopsy Devices Market

• Saudi Arabia: Saudi Arabia recorded USD 18.22 million in 2025, projected to grow steadily toward USD 36.50 million by 2034, driven by healthcare modernization at a 7.98% CAGR.
• South Africa: South Africa’s market size was USD 14.86 million in 2025, forecasted to hit USD 29.51 million by 2034, sustaining strong regional diagnostics at a 7.96% CAGR.
• United Arab Emirates: UAE recorded USD 10.55 million in 2025, projected to reach USD 20.89 million by 2034, supported by advanced hospital expansion at a 7.93% CAGR.
• Egypt: Egypt achieved USD 8.71 million in 2025, expected to reach USD 17.12 million by 2034, reflecting continued growth in prostate diagnostics adoption at a 7.92% CAGR.
• Nigeria: Nigeria recorded USD 6.71 million in 2025, projected to achieve USD 13.01 million by 2034, highlighting emerging diagnostic demand expansion at a 7.90% CAGR.

List of Top Prostate Biopsy Devices Companies

• Sterylab
• Bard
• Invivo
• Biomedical
• Argon Medical Devices
• Geotekmedical
• UROMED
• Amecath
• BD
• Cook Medical
• TSK

Top Two Companies by Market Share:

• Bard held approximately 24% of global market presence in 2023 due to its strong biopsy needle portfolio.
• Cook Medical accounted for nearly 18% of global share, driven by its wide distribution and advanced biopsy systems.

Investment Analysis and Opportunities

The Prostate Biopsy Devices Market presents significant opportunities for investment in advanced diagnostic technologies. Rising healthcare expenditure globally, which surpassed 10% of GDP in many developed countries, is supporting procurement of robotic-assisted and MRI-guided devices. In emerging economies, government-led initiatives are strengthening early cancer detection programs, generating demand for cost-effective biopsy solutions.

Data from 2023 indicates that nearly $15 billion was invested globally in oncology diagnostics equipment, with prostate biopsy devices capturing a growing portion of that funding. Hospitals and research institutions are actively pursuing partnerships with device manufacturers to develop precision biopsy tools. With an estimated 1.4 million new prostate cancer cases annually, the investment outlook in biopsy device manufacturing, distribution, and training remains robust.

New Product Development

Innovation in prostate biopsy devices has accelerated in recent years, with companies introducing advanced systems for precision targeting and patient safety. MRI-ultrasound fusion devices are being adopted widely, with clinical trials showing detection accuracy of up to 92% for clinically significant cancers.

Manufacturers are focusing on disposable needle technology, with innovations reducing infection risks by nearly 95%. Robotic-assisted biopsy platforms are also entering the market, with systems enabling accuracy improvements of 20% compared to conventional biopsy methods. AI integration in diagnostic imaging has improved biopsy guidance accuracy by nearly 18%, making procedures more reliable.

Five Recent Developments

• In 2023, Bard launched a next-generation disposable biopsy needle with infection risk reduction of 96%.
• Cook Medical expanded its robotic biopsy device line in 2024, improving targeting accuracy by 21%.
• BD introduced AI-supported biopsy imaging software in 2023, boosting precision by 17%.
• Argon Medical Devices released a reusable biopsy gun in 2024 capable of 600 sterilization cycles.
• Invivo partnered with hospitals in 2025 to deploy MRI-fusion systems across 45 diagnostic centers worldwide.

Report Coverage of Prostate Biopsy Devices Market

The Prostate Biopsy Devices Market Report provides detailed insights into the global landscape, highlighting device adoption, technological advancements, segmentation, and regional performance. Covering over 1.4 million prostate cancer cases annually, the report emphasizes the role of biopsy devices in accurate diagnosis.

The report covers key device categories, including reusable and disposable biopsy systems, as well as application across hospitals, ASCs, and diagnostic centers. Regional analysis spans North America, Europe, Asia-Pacific, and Middle East & Africa, with market share data showing 41%, 28%, 22%, and 9% respectively.

Prostate Biopsy Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 699.93 Million in 2026
Market Size Value By	USD 1395.25 Million by 2035
Growth Rate	CAGR of 7.97% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Reusable Devices Disposable Devices By Application : Hospitals Ambulatory Surgical Center (ASCs) Diagnostic Centers
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample